source
- Dual targeting of GPCRs and mutated Gαq/11 shows promise for uveal melanomaResearchers at Thomas Jefferson University reported a new strategy to disrupt signaling in uveal melanoma, a rare eye cancer. The study found that simultaneously inhibiting the G protein-coupled r…
- Neurosterix raises $105 million Series B to advance schizophrenia candidateNeurosterix announced it has closed a $105 million Series B financing round. The capital will be used to develop its lead drug candidate for schizophrenia, which targets a pathway also addressed by…